Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cumberland Pharmaceuticals ( (CPIX) ) has issued an announcement.
On February 4, 2026, Cumberland Pharmaceuticals announced that the U.S. Food and Drug Administration granted Fast Track Designation to its oral thromboxane receptor antagonist ifetroban, which targets a fatal form of heart disease in Duchenne muscular dystrophy patients. The designation, which follows prior Orphan Drug and Rare Pediatric Disease status for ifetroban and is supported by positive Phase 2 data showing a 5.4% improvement in left ventricular ejection fraction over 12 months, is expected to accelerate regulatory interactions and review, potentially strengthening Cumberland’s position in rare disease cardiology and offering new hope in an area where no approved therapies currently exist for DMD-related heart disease.
The most recent analyst rating on (CPIX) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Cumberland Pharmaceuticals stock, see the CPIX Stock Forecast page.
Spark’s Take on CPIX Stock
According to Spark, TipRanks’ AI Analyst, CPIX is a Neutral.
The score is held back primarily by weak profitability and declining TTM revenue despite strong gross margins, with valuation also constrained by negative earnings (negative P/E). Partially offsetting this are improving leverage and positive operating cash flow, plus favorable earnings-call developments (Talicia partnership, international progress, and YTD revenue growth). Technically, momentum is strong but appears overheated, which tempers the upside.
To see Spark’s full report on CPIX stock, click here.
More about Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) is a specialty pharmaceutical company focused on developing new products for rare diseases, with a particular emphasis on therapies that address serious unmet medical needs, such as novel treatments for heart complications associated with Duchenne muscular dystrophy (DMD).
Average Trading Volume: 180,757
Technical Sentiment Signal: Strong Buy
Current Market Cap: $57.73M
For an in-depth examination of CPIX stock, go to TipRanks’ Overview page.